Title
In vivo 1H MRS of human gallbladder bile at 3T in one and two dimensions: Detection and quantification of major biliary lipids

Permalink
https://escholarship.org/uc/item/1m02c6tx

Authors
Mohajeri, S
Ijare, OB
Bezabeh, T
et al.

Publication Date
2014

DOI
10.1002/nbm.3173

Peer reviewed
**In vivo** 1H MRS of human gallbladder bile at 3 T in one and two dimensions: detection and quantification of major biliary lipids†

Sanaz Mohajeri, Omkar B. Ijare, Tedros Bezabeh, Scott B. King, M. Albert Thomas, Gerald Minuk, Jeremy Lipschitz, Iain Kirkpatrick, Mike Smith and Ian C. P. Smith

In vitro 1H MRS of human bile has shown potential in the diagnosis of various hepatopancreatobiliary (HPB) diseases. Previously, in vivo 1H MRS of human bile in gallbladder using a 1.5 T scanner demonstrated the possibility of quantification of choline-containing phospholipids (chol-PLs). However, other lipid components such as bile acids play an important role in the pathophysiology of the HPB system. We have employed a higher magnetic field strength (3 T), and a custom-built receive array coil, to improve the quality of in vivo 1H MRS of human bile in the gallbladder. We obtained significant improvement in the quality of 1D spectra (17 healthy volunteers) using a respiratory-gated PRESS sequence with well distinguished signals for total bile acids (TBAs) plus cholesterol resonating at 0.66 ppm, taurine-conjugated bile acids (TCBAs) at 3.08 ppm, chol-PLs at 3.22 ppm, glycine-conjugated bile acids (GCBAs) at 3.74 ppm, and the amide proton (−NH) arising from GCBAs and TCBAs in the region 7.76–8.05 ppm. The peak areas of these signals were measured by deconvolution, and subsequently the molar concentration of TBAs plus cholesterol was overestimated in some cases, which could be due to lipid contamination. In addition, we report the first 2D L-COSY spectra of human gallbladder bile in vivo (obtained in 15 healthy volunteers). 2D L-COSY spectra will be helpful in differentiating various biliary chol-PLs in pathological conditions of the HPB system. Copyright © 2014 John Wiley & Sons, Ltd.

**Keywords**: human bile; in vivo 1H MRS; glycine-conjugated bile acids; taurine-conjugated bile acids; choline-containing phospholipids; PRESS; L-COSY

**INTRODUCTION**

Bile is a yellowish green fluid secreted by liver, stored and concentrated in the gallbladder and released to the duodenum in response to cholecystokinin following ingestion of food (1). It is mainly composed of water, pigments such as bilirubin, lipids including choline-containing phospholipids (chol-PLs), cholesterol, and bile salts such as glycine-conjugated bile acids (GCBAs) and taurine-conjugated bile acids (TCBAs) (2–4). Bile salts play a major role in emulsification, digestion, and absorption of lipids. Moreover, the common bile duct receives pancreatic secretions through the pancreatic duct before emptying to the duodenum (2). Therefore, the metabolic profile of bile delivered to the intestine is mainly under the control of cellular secretions of liver, gallbladder, pancreas, and bile ducts. As a result, any pathological changes in the gastrointestinal system, especially the hepatopancreatobiliary (HPB) part, can affect the metabolic profile of the bile (1–4). Among these metabolites, cholesterol, chol-PLs, and bile acids have captured more attention, due to their higher concentration and greater role in the disease processes (4–8).

Various in vitro studies have demonstrated the potential of MRS in the diagnosis of HPB pathologies, especially in differentiating benign changes from malignant ones through analysis of chol-PLs, bile acids, and cholesterol in the bile (4,6,7,9). The recent success from our laboratory in the simultaneous quantification of bile acids

---

**Abbreviations used**: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; chol-PLs, choline-containing phospholipids; DSS, 3-(trimethylsilyl)-1-propanesulfonic acid sodium salt; ERCP, endoscopic retrograde cholangiopancreatography; FID, free induction decay; GCBAs, glycine-conjugated bile acids; GDCA, glycodeoxycholic acid sodium salt; GGT, gamma-glutamyl transferase; HASTE, half-Fourier acquisition single-shot turbo spin-echo; HPB, hepatopancreatobiliary; INR, international normalized ratio; PC, phosphatidylcholine; Phe, phosphocholine chloride calcium salt tetrahydrate; TBAs, total bile acids; TCA, taurocholic acid sodium salt; TCBAs, taurine-conjugated bile acids; TReff, effective TR.
changes in the concentrations of the key metabolic footprints of different HPB disorders (10). Moreover, analyzing the ratio of concentrations of metabolites can also provide additional diagnostic information. For example, in our previous study (11) comparing cholestatic hyperbilirubinemic hepatobiliary patients with normobilirubinemic cases, the ratio of biliary GCBAs to TCBAs was found to decrease by an amount that was statistically significant. However, the changes in the concentrations of the individual GCBAs and TCBAs were not statistically significant.

Analysis of bile spectra has its own difficulties. The similarities in the structures of constituent bile acids in bile may result in significant overlap of peaks of interest, especially in in vivo MRS studies. To overcome such difficulties, different NMR methods have been developed (12,13). Spectral editing MRS sequences may overcome this problem (14), but they can only measure one metabolite at a time. However, 2D MRS techniques such as COSY may virtually separate multiple overlapping peaks in a single measurement, providing unambiguous assignment. Therefore, they may become the techniques of choice in such cases (15,16).

For years, providing metabolic information using MRS non-invasively was difficult, primarily due to the complexities of in vivo MRS. The challenges include overlapping of metabolite peaks due to the use of lower magnetic field strengths (typically 1.5 T, compared with 9.4–14.1 T for in vitro studies), magnetic susceptibility effects, and motion artifacts (17). Advances in MR technology, at the levels of both hardware and software, have decreased such bottleneck areas to a large extent. The increase in magnetic field strength of clinical scanners (≥3 T), and the development of gated sequences (to minimize the effect of motion artifacts), has been quite helpful. As a result, there has been a great interest in the detection and quantification of bile metabolites with diagnostic potential using in vivo 1H MRS (18,19). Prescott et al. performed the first in vivo 1H MRS study on human gallbladder bile, using a 1.5 T MRI scanner and a surface coil in receive mode (18). However, the published in vivo spectra were of low quality, and the authors were unable to quantify individual bile components other than chol-PLs. This could be due to the lower magnetic field strength (1.5 T), use of a spin echo sequence with long delays (T_E = 60 ms), and/or lipid contamination (18). Künecke et al. were successful in obtaining a better quality spectrum of bile in vivo in cynomolgus monkeys using a 4.7 T animal scanner and a custom-built surface coil in transmit-receive mode with the aid of a respiratory-gated sequence (19). They identified and quantified different bile component peaks, bile acids, and their taurine and glycine conjugates, including the previously reported chol-PLs (19).

Our preliminary study on pigs using a 3 T clinical scanner and a custom-built receive array coil revealed a significant improvement in the quality of in vivo 1H spectra of gallbladder bile (20,21). The resultant spectra were promising enough to recommend exploring the possibility of acquiring such spectra in humans. In the current study, we report 1D 1H MRS of human gallbladder bile at 3 T, including the detection and quantification of major lipid components. In addition, we report the first acquisition of 2D L-COSY data for human gallbladder bile in vivo.

METHODS

Subject characteristics

Healthy volunteers were recruited at the National Research Council (NRC) and Health Sciences Centre, University of Manitoba, Winnipeg, according to the protocol approved by the Research Ethics Boards of the University of Manitoba and the NRC. Informed consent was obtained from each subject and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. The subjects had no history of acute or chronic liver disease, inflammatory bowel disease or heavy alcohol use (≥3 drinks/day). None of the subjects was on medication that could cause liver toxicity. The possibility of active HPB disorders was ruled out in all subjects using a combination of medical history, physical examination, and laboratory blood tests including bilirubin (total and direct), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), lipase, alkaline phosphatase (ALP), and international normalized ratio (INR).

After optimizing the scanning parameters on a number of healthy volunteers, MRS data were acquired from 22 subjects. We collected 1D data from 17/22 subjects and 2D data from 15/22 subjects. We were able to acquire both 1D and 2D data in 7/22 subjects. Out of the 17 1D spectra, 3 were excluded due to lipid contamination, ineffective water suppression, or motion artifacts due to failed respiratory gating. The 14 subjects included in the final 1D analysis comprised 11 females and 3 males (mean ages 40 and 33 respectively, range 21–55). In the case of 2D, data from 4/15 subjects were excluded due to low SNR and the same issues described above. The 11 subjects included in the final 2D analysis were 7 females and 4 males (mean ages 41 and 35 respectively, range 26–55). Details of the subjects’ characteristics and biochemical data are given in Table 1.

MRS experiments

MRS experiments were performed on a Siemens 3 T Magnetom Trio clinical scanner (RF transmitter frequency = 123.22 MHz). The body coil transmitted the RF pulses. A custom-built surface receive array coil, which passed the safety checks of the NRC and was approved by the research ethics boards of both the NRC and the University of Manitoba, was used as an RF receiver. Single voxel spectroscopy was performed using the PRESS sequence with bellow respiratory gating (VB15 and VB17, Siemens, Erlangen, Germany). 1D experiments were performed on solutions of phosphocholine chloride calcium salt tetrahydrate (PhC), taurocholic acid sodium salt (TCA), and glycodeoxycholic acid sodium salt (GDCa), representing three major biliary biochemicals – chol-PLs, TCBAs, and GCBAs, respectively. These experiments were used to verify the accuracy of quantification of chol-PLs, TCBAs, and GCBAs in the bile at 3 T. The 1D 1H spectra were then acquired from human gallbladder bile in vivo. Finally, we edited the PRESS sequence to L-COSY as described by Thomas et al. (15). In this method, the last 180° refocusing pulse of the PRESS sequence was replaced by a hyperbolic secant 90°, the same as the first 90° excitation RF pulse, and a 0.8 ms time increment (Δt_e) was applied between the first refocusing and the second 90° (coherence transfer) RF pulse in each measurement (15). In both 1D and 2D experiments, we optimized the voxel size to 12 x 12 x 12 mm^3 to minimize the effect of lipid contamination from the liver or the body fat outside the gallbladder. Spatial saturation bands were positioned around the gallbladder in order to further minimize such effects. Application of bellow respiratory-gated sequences reduced the extent of motion artifact due to breathing. With manual shimming, we achieved a full width half-maximum of less than 15 Hz. The bandwidth of the water suppression pulses was adjusted to 35 Hz on
In vitro phantom measurements

Aqueous solutions of PhC, TCA, and GDCA, representing the major bile components (cholester-PLs, TCBAs, and GCBAs), were prepared based on a method described in the LCModel User's Manual (22). Each phantom contained a solution of a metabolite with identical to those mentioned above. A 12 × 12 × 12 mm3 voxel was positioned in the gallbladder using these images. Six spatial saturation bands were positioned around the gallbladder in order to reduce lipid contamination. After adjusting the frequency and setting the receiver gain to high, manual shimming and water suppression were performed. PRESS sequence. The following acquisition parameters were used: voxel size = 12 × 12 × 12 mm3, TE = 30 ms, TR = 10000 ms, bandwidth = 2000 Hz, vector size = 2048 points, and Ns = 256. A second spectrum with eight scans was acquired from the same voxel using the same parameters but without water suppression in each experiment.

In vivo measurements

The subjects fasted for at least 4 h before the study. Three orthogonal MR images were used to localize the gallbladder. The images were obtained during breath hold at the end of a regular expiration using HASTE sequences with acquisition parameters identical to those mentioned above. A 12 × 12 × 12 mm3 voxel was positioned in the gallbladder using these images. Six spatial saturation bands were positioned around the gallbladder in order to reduce lipid contamination. After adjusting the frequency and setting the receiver gain to high, manual shimming and water suppression were performed. 1D spectra were obtained using the bellow respiratory-gated PRESS sequence during the last 10–30% of quiet expiration. The acquisition parameters were the same as those of in vitro experiments except for TR, which was 2000 ms. We used the minimum possible TE (30 ms) of the Siemens instrument in order to reduce signal loss due to T2 relaxation. Although the TR was 2000 ms, one free induction decay (FID) was recorded in each breath. Therefore, the effective TR (TReff) was considered to be equal to the average breathing cycle length in each subject. Considering that the scanning time obtained for each sequence from the scanner includes the adjustment time, we could not use the water suppressed 1D or 2D spectra to calculate TReff. Since the unsuppressed water 1D spectrum was acquired immediately after the 1D spectrum with

Table 1. Age, sex, and blood biochemistry of healthy volunteers participating in the study

| Subject | Age | Sex | Bilirubin total (μM) | Bilirubin direct (μM) | AST (U/L) | ALT (U/L) | GGT (U/L) | Lipase (U/L) | ALP (U/L) | INR
|---------|-----|-----|---------------------|---------------------|-----------|-----------|-----------|-------------|-----------|-----
| 1       | 41  | F   | 9                   | 3                   | 22        | 14        | —         | 69          | 77        | —   |
| 2       | 43  | M   | 5                   | 2                   | 21        | 19        | —         | 40          | 69        | 1.2 |
| 3       | 21  | F   | 7                   | —                   | 19        | 20        | —         | 31          | 74        | 0.9 |
| 4*      | 26  | F   | 6                   | <2                  | 17        | 15        | 13        | 30          | 41        | 1   |
| 5*      | 36  | F   | 20                  | 4                   | 22        | 13        | 22        | 35          | 51        | —   |
| 6*      | 54  | F   | 8                   | 2                   | 23        | 14        | 18        | 30          | 84        | 1   |
| 7*      | 27  | M   | —                   | 5                   | 31        | 24        | 14        | 20          | 80        | 1   |
| 8       | 55  | F   | 3                   | <2                  | 22        | 20        | —         | 44          | 86        | 1.1 |
| 9       | 31  | F   | 4                   | <2                  | 19        | 17        | —         | 84          | 50        | 1   |
| 10      | 44  | F   | 10                  | <2                  | 20        | 12        | 11        | 41          | 43        | 1   |
| 11*     | 26  | F   | 13                  | 3                   | 19        | 14        | 14        | 35          | 50        | 1   |
| 12      | 49  | F   | 4                   | <2                  | 20        | 15        | 14        | 50          | 59        | 0.9 |
| 13*     | 54  | F   | 6                   | <2                  | 20        | 17        | 10        | —           | 73        | 0.9 |
| 14*     | 29  | M   | 15                  | 3                   | 35        | 17        | 13        | 46          | 71        | 1   |
| 15*     | 36  | M   | 9                   | 2                   | 19        | 21        | —         | 45          | 102       | 1   |
| 16*     | 49  | M   | 3                   | <2                  | 22        | 43        | 37        | 39          | 72        | 1   |
| 17*     | 55  | F   | 4                   | <2                  | 24        | 15        | 20        | 45          | 75        | 1   |
| 18*     | 38  | F   | 8                   | <2                  | 26        | 33        | 35        | 23          | 55        | 0.9 |

*—, not reported by the clinical laboratory; *, participated in both 1D and 2D experiments; #, participated only in 2D experiments.

μM, micromolar; U/L, unit/liter; M, male; F, female.

Normal values of blood biochemistry: bilirubin total, 2–20 μM; bilirubin direct, <7 μM; AST, 10–32 U/L; ALT, M, <30, F, <25 U/L; GGT, M, 5–38, F, 5–29 U/L; lipase, <60 U/L; ALP, 30–120 U/L; INR, 0.9–1.1.
the same parameters (no need for adjustments), we used these data for calculating $T_{Reff}$. We divided the scanning time by the number of scans to calculate the average breathing cycle length, which was equal to $T_{Reff}$. As a result, the $T_{Reff}$ in different subjects was variable in the range of 3750–7438 ms, and the mean of $T_{Reff}$ in all subjects was 5366 ms. Therefore, our spectra in most cases were almost fully relaxed. $N_s$ was 256 except in one case, which was 128. The average time for gallbladder localization, adjustment of parameters, and data acquisition was 42 min. Considering that the average $T_{Reff}$ was 5366 ms, the average time for 256 scans was 22.89 min. The rest of the time was needed for acquiring localization images, manual adjustments (specially shimming and water suppression), and acquiring the 1D spectrum with unsuppressed water.

**Two-dimensional in vivo $^1$H MR experiments**

Although it is possible to identify and quantify different metabolites using 1D $^1$H MRS, the presence of overlapping signals from structurally similar metabolites makes the identification of some of the resonances very challenging. Therefore, we made use of 2D L-COSY experiments to detect some of these signals unambiguously (15,16). A $12 \times 12 \times 12$ mm$^3$ voxel was positioned in the gallbladder using the three orthogonal localizer images. Spatial saturation bands were positioned around the gallbladder to reduce lipid contamination. After adjusting the frequency, and setting the receiver gain to high, manual shimming and water suppression were performed. 2D L-COSY data were acquired during the last 10–30% of quiet expiration using the bellow respiratory-gated sequence. The following spectral parameters were used throughout: $T_e = 30$ ms, $T_R = 2000$ ms, bandwidth = 2000 Hz, vector size = 2048 points, $N_s = 12$, time increment ($\Delta t$) = 0.8 ms, and number of measurements = 50 or 64 except in one case, which had only 40 measurements. The original minimum $T_R$ was set to 2000 ms. Considering that in each breath one FID was recorded, the $T_{Reff}$ was variable. The approximate time for adjusting parameters and the collection of 2D data was 49 min. In the majority of cases, since the 2D data were acquired right after 1D, there was no need to repeat the localizers and we used the adjusted parameters from 1D as a guideline and performed only fine adjustments (which took a very short time). As a result, if we ignore the adjustment time, the average $T_{Reff}$ for 2D will be 4548 ms, which is shorter than that for 1D. The maximum $T_1$ relaxation time for our metabolites of interest presented in Table 2 is 383 ms (for TCBAs). If we have $T_R > 5 T_1$ ($5 \times 383 = 1915$ ms), then the spectrum will be fully relaxed. The range of $T_{Reff}$ for 2D experiments was 3672–5700 ms. Moreover, by choosing the minimum possible $T_R$ of 2000 ms, we made sure that the variation in $T_{Reff}$ did not affect the qualitative analysis of the 2D data.

**Data processing**

1D $^1$H MR experiments

The raw data (meas files from the Siemens scanner) were first processed by an in-house MATLAB program generated at UCLA (Dr Thomas’s laboratory), and modified at NRC. This program facilitated the inspection of individual scans. The scans which were distorted by lipid contamination, failed water suppression or with very low SNR (no detectable signal) were discarded. Out of the 256 scans acquired, 216 undistorted scans were averaged in all subjects except for two cases. In the first case, only 128 scans were acquired due to time limitation. Out of 128 scans, 119 were analyzed after eliminating the distorted scans. In the other case, out of 256 scans only 52 were analyzed. The individual spectra in all scans were aligned (using the methylene ($-\text{CH}_2-$) proton signal of the lipid peak at 1.26 ppm or the trimethylammonium ($-N^+\text{(CH}_3)_3$) signal of chol-PLs at 3.22 ppm) to minimize frequency drifts due to breathing motion artifacts, and then averaged. Eddy current correction was applied using the unsuppressed water signal (23) and the data from individual coil elements were combined using an optimized method based on noise correlation (24). After this preliminary processing, the data were transferred to FELIX-2007 software (FELIX NMR, San Diego, CA, USA). The data were then apodized using an exponential function with a line broadening of 0.5 Hz, and Fourier transformed. First and second order phase and baseline corrections were applied on the real part of the spectrum. Finally, the spectrum was referenced to the lipid $-\text{CH}_2-$ peak at 1.26 ppm or the $-N^+\text{(CH}_3)_3$ signal of chol-PLs at 3.22 ppm. The data acquired from phantom solutions were processed similarly. The first 216 scans were averaged and the spectrum was referenced to the DSS signal at 0 ppm.

**Quantification of biliary biochemicals**

Chemical shift assignments in the bile $^1$H spectrum were made according to the previous in vitro (10,12) and in vivo studies on human (18) and monkey bile (19). Twenty-one different peaks in the water-suppressed bile $^1$H spectrum were fitted to Lorentzian line shapes by deconvolution based on a simulated annealing algorithm (FELIX NMR). Similarly, the water peak of the bile spectrum obtained without water suppression was fitted and used as an internal reference. After fitting, the peak areas of the methyl ($-\text{CH}_3$) signal representing TCBAs plus cholesterol at 0.66 ppm, the $-\text{CH}_2-$ signal of TCBAs at 3.08 ppm, the $-N^+\text{(CH}_3)_3$ signal of chol-PLs at 3.22 ppm, the $-\text{CH}_2-$ signal of GCBAs at 3.74 ppm, and the amide signals ($-\text{NH}$) of GCBAs and TCBAs in the region 7.76–8.05 ppm were measured. Molar concentrations of all the above biliary lipids were calculated using the following equation, similar to that reported by Fayad et al. (25):

| Table 2. $T_1$, $T_2$ relaxation times of major bile metabolites calculated using porcine bile |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Metabolite | TBAs 0.65 ppm | TCBAs 3.01 ppm | chol-PLs 3.22 ppm | GCBAs 3.74 ppm | GCBAs + TCBAs 7.95 ppm | Water 4.78 ppm |
| $T_1$ value (ms) | 233 | 383 | 298 | 360 | 352 | 780 |
| $T_2$ value (ms) | 25 | 93 | 155 | 84 | 36 | 172 |

$T_1$ and $T_2$ relaxation times were calculated using FELIX 2007 software.

*, porcine bile used for $T_1$ and $T_2$ measurements showed an additional peak at 3.15 ppm in the chol-PL region.
where \( CF(H_2O) = 0.9 \) is a conversion factor for the water content of human gallbladder bile, which is considered to be 90% by weight (26), \( fT_1 = 1 - \exp(-T_1/T_1) \) and \( fT_2 = \exp(-T_2/T_2) \) are correction factors due to the \( T_1 \) and \( T_2 \) relaxation times of water and individual lipid molecules and were calculated as reported elsewhere (25,27) and presented in Table 2. In order to confirm the accuracy of the calculations, the peak areas of the signals acquired from phantom solutions were also quantified similarly.

### RESULTS

Figure 1 represents the \(^1H\) spectra of PhC, TCA and GDCA solutions representing three major biliary biochemicals – chol-PLs, TCBAs and GCBAs. The assignment of peaks and their selection for the quantification was based on the results from previous in vitro (10,12) and in vivo (18,19) studies. Figure 1(A) shows the \(^1H\) MR spectrum of an aqueous solution of PhC. We used PhC instead of phosphatidylcholine (PC) due to the similarity of its head group with that of PC and also due to its free solubility in water. The peak at 3.20 ppm was assigned to the –N\(^{+}\)(CH\(_3\))\(_3\) group of PhC. Figure 1(B) was obtained from the phantom solution of TCA representing TCBAs. The triplet at 3.06 ppm is due to its H-26 –CH\(_2\) – signal, whereas peaks at 0.68 and 7.99 ppm were assigned to the H-18 –CH\(_3\) and amide (–NH) groups of TCBAs respectively. Figure 1(C) represents the spectrum recorded from a GDCA solution. The signals resonating at 0.68, 3.72 and 7.83 ppm were assigned to the H-18 –CH\(_3\), the H-25 –CH\(_2\) – and the amide (–NH) group of GCBAs respectively. All these spectra were recorded using a TR of 10000 ms and TE of 30 ms, ensuring complete relaxation and with negligible T2 loss.

\( T_1 \) and \( T_2 \) relaxation times of various bile metabolites were measured using porcine bile. Table 2 lists the \( T_1 \) and \( T_2 \) values of major bile metabolites quantified in this study, including water, which was used as an internal reference. Table 3 lists actual and calculated concentrations of biochemicals from phantom solutions determined using current quantification methodology. The concentrations of metabolites before and after applying \( T_1 \) and \( T_2 \) corrections were compared with the actual concentration of each phantom solution to prove the reliability of the quantification. The concentrations of metabolites determined after applying both \( T_1 \) and \( T_2 \) corrections were very close to the actual concentrations, except for GCBAs, which were quantified using the amide (–NH) signal resonating at 7.83 ppm.

![Figure 1](https://example.com/figure1.png) **Figure 1.** \(^1H\) spectra of (A) PhC, (B) TCA and (C) GDCA solutions representing three major biliary biochemicals – chol-PLs, TCBAs and GCBAs respectively. The signals were assigned based on the previous in vitro (10,12) and in vivo studies (18,19). Assignments: 0, DSS; 7, –N\(^{+}\)(CH\(_3\))\(_3\) group of PhC; 9, residual water; 1a, H-18 protons of –CH\(_3\) group of TCA; 6, H-26 protons of –CH\(_2\) – group of TCA; 11a, amide (–NH) group of TCA; 1b, H-18 protons of –CH\(_3\) group of GDCA; 8, H-25 protons of –CH\(_2\) – group of GDCA; 11b, amide (–NH) group of GDCA.

<table>
<thead>
<tr>
<th>Metabolite (peak used)</th>
<th>PhC (3.20 ppm)</th>
<th>TCA (0.68 ppm)</th>
<th>TCA (7.99 ppm)</th>
<th>GDCA (0.68 ppm)</th>
<th>GDCA (3.72 ppm)</th>
<th>GDCA (7.83 ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentration (mM)</td>
<td>22.69</td>
<td>7.08</td>
<td>11.26</td>
<td>13.74</td>
<td>32.41</td>
<td>37.04</td>
</tr>
<tr>
<td>Corrected concentration (mM)</td>
<td>23.13</td>
<td>19.74</td>
<td>21.77</td>
<td>38.31</td>
<td>38.90</td>
<td>71.59</td>
</tr>
<tr>
<td>Solution concentration (mM)</td>
<td>21.24</td>
<td>20.18</td>
<td>20.18</td>
<td>37.42</td>
<td>37.42</td>
<td>37.42</td>
</tr>
</tbody>
</table>

### Table 3. Concentration of metabolites (mM) before and after \( T_1 \) and \( T_2 \) corrections compared with the actual concentrations of phantom solutions

---

wileyonlinelibrary.com/journal/nbm

Copyright © 2014 John Wiley & Sons, Ltd.

From Table 3, it is clear that no corrections were required for the quantification of GCBAs determined using their amide signal. Since the amide peak in human/porcine bile is a combination of both TCBAs and GCBAs, the $T_1$ and $T_2$ corrections are mainly required for the amide signal of TCBAs. Since the $H-26-CH_2-$ signal of TCA at 3.06 ppm (peak 6 in Fig. 1(B)) had an apparent phasing problem, the quantification of this signal in the phantom experiments was not feasible.

Figure 2 illustrates a typical $^1$H MR spectrum recorded from the gallbladder bile of a healthy volunteer in vivo at 3 T using a custom-built receive-only coil. Panels (A)–(C) represent three orthogonal images acquired at the end of expiration during a regular breath-hold in order to position a $12 \times 12 \times 12 \text{mm}^3$ voxel in the gallbladder. Panel (D) shows the corresponding $^1$H MR spectrum obtained from this voxel. The majority of signals belong to major biliary lipids – chol-PLs, cholesterol and various bile acids. The peaks were assigned based on the in vitro studies performed by Ijare et al. (10) and Gowda et al. (12) and the in vivo studies on human (18) and monkey bile (19). The signal at 0.66 ppm, marked as peak 1, was assigned to the $-CH_3$ group of TBA($H$-18 protons). This peak has contributions from cholesterol as well (10,19). Peak 2 at 0.88 ppm was assigned to protons of the ring bound $-CH_3$ group of bile acids ($H$-19 protons). Peak 3 in the region 0.99–1.02 ppm was assigned to the $H-21-CH_3$ protons of bile acids (12,19). The signal at 1.26 was assigned to the $-CH_2-$ protons of the aliphatic tail of phospholipids (peak 4). A group of overlapping peaks in the region 1.45–2.73 ppm (region 5) represents the remainder of the aliphatic protons in bile acids, chol-PLs and cholesterol (10,19). The $N^+$(CH$_3$)$_3$ group of chol-PLs was observed at 3.22 ppm, peak 7 (10,18,19). The peak at 3.08 ppm (peak 6) was assigned to the $H-26-CH_2-$ group of TCBAs, whereas the signal at 3.74 ppm was assigned to the H-25 $-CH_2-$ group of GCBAs (peak 8). The olefinic ($-CH=CH-$) protons of chol-PLs resonate at 5.28 ppm, marked as peak 10 (19). Lastly, the broad overlapping peaks (peak 11) resonating in the region 7.76–8.05 ppm were assigned to the amide (–NH) groups of both GCBAs and TCBAs (10,19). Panel (E) compares the actual spectrum of human bile in vivo (bottom) with its synthesized spectrum obtained by FELIX-2007 software, based on Lorentzian fitting (middle), and the residual spectrum (top). Out of the 17 spectra obtained from healthy volunteers, 14 were included in the quantification (see Table 1 for details).

Peaks of bile metabolites with a known role in HPB disorders (7–11,17,28), and which were resolved in the in vivo $^1$H MR spectrum, were selected for the quantification (i.e. peaks 1, 6, 7, 8, and 11 in panel (D)). Table 4 lists the concentrations (mM) of metabolites quantified after applying $T_1$, $T_2$ and CF($H_2$O) corrections as discussed in the methods section. The means and standard deviations for TBA$+$ plus cholesterol, TCBAs, GCBAs and chol-PLs were calculated. From Table 4, it is obvious that the mean

Figure 2. $^1$H MR spectrum of human gallbladder bile acquired from a healthy volunteer in vivo with a 3 T Siemens scanner using a custom-built receive-only coil. (A)–(C) Transverse, coronal and sagittal images acquired at the end of expiration during a regular breath-hold and used for the positioning of a $12 \times 12 \times 12 \text{mm}^3$ voxel in the gallbladder. (D) The corresponding $^1$H MR spectrum of gallbladder bile obtained from this voxel. The peaks were assigned based on the previous in vitro (10,12) and in vivo (18,19) studies. Assignments: 1, H-18 protons of $-CH_3$ group of TBA$+$ (this peak also has a contribution from cholesterol $H$-18 protons of the $-CH_3$ group); 2, protons from the ring bound $-CH_3$ group of bile acids ($H$-19 protons); 3, in the region 0.99–1.02 ppm was assigned to the $H-21-CH_3$ protons of bile acids (12,19). The signal at 1.26 was assigned to the $-CH_2-$ protons of the aliphatic tail of phospholipids (peak 4). A group of overlapping peaks in the region 1.45–2.73 ppm (region 5) represents the remainder of the aliphatic protons in bile acids, chol-PLs and cholesterol (10,19). The $N^+$(CH$_3$)$_3$ group of chol-PLs was observed at 3.22 ppm, peak 7 (10,18,19). The peak at 3.08 ppm (peak 6) was assigned to the $H-26-CH_2-$ group of TCBAs, whereas the signal at 3.74 ppm was assigned to the H-25 $-CH_2-$ group of GCBAs (peak 8). The olefinic ($-CH=CH-$) protons of chol-PLs resonate at 5.28 ppm, marked as peak 10 (19). Lastly, the broad overlapping peaks (peak 11) resonating in the region 7.76–8.05 ppm were assigned to the amide (–NH) groups of both GCBAs and TCBAs (10,19). Panel (E) compares the actual spectrum of human bile in vivo (bottom) with its synthesized spectrum obtained by FELIX-2007 software, based on Lorentzian fitting (middle), and the residual spectrum (top).
concentrations of all the quantified metabolites were well within the range of biliary biochemicals reported earlier (10,18,29).

Figure 3 shows the 2D L-COSY spectrum of human gallbladder bile obtained in vivo from healthy volunteers. This is the first report of an in vivo 2D L-COSY spectrum of human gallbladder bile. Figure 3(A) shows a typical in vivo 2D spectrum of bile with water suppression band width of 35 Hz and 50 increments, Fig. 3(B) represents a 2D spectrum with water suppression band width of 50 Hz and 50 increments, and Fig. 3(C) shows a 2D spectrum with water suppression band width of 35 Hz and 39 increments. In this case, although 50 measurements were acquired, only the first 39 measurements were processed due to technical issues. All three spectra are linear predicted to 64 increments. The diagonal peak at $F_1 = 7.82 \pm 0.04 \text{ ppm}$ represents the amide group of TCBAs (marked as 1, detected in 11/11 cases). The diagonal peak at $F_2 = F_1 = 3.21 \pm 0.01 \text{ ppm}$ was assigned to the PC-cholyl $N'\text{--CH}_2$–protons (marked as 4, detected in 11/11 cases), and the symmetric cross peaks at $F_2 = 4.34 \pm 0.05$, $F_1 = 3.68 \pm 0.05 \text{ ppm}$ and $F_2 = 3.66 \pm 0.02$, $F_1 = 4.39 \pm 0.14 \text{ ppm}$ represent $J$-coupling between the $-N\text{--CH}_2$– and $-CH_2\text{--O}^\text{--}$ of chol-PLs (marked as 4a and 4b, detected in 6/11 cases). The diagonal peak at $F_2 = F_1 = 3.21 \pm 0.01 \text{ ppm}$ was assigned to the $N'(\text{CH}_3)_3$ group of chol-PLs (marked as 5, detected in 11/11 cases). The diagonal peak at $F_2 = F_1 = 3.06 \pm 0.03 \text{ ppm}$ (marked as 6, detected in 11/11 cases) was assigned to the H-26–$CH_2$–protons of TCBAs along with the cross peak at $F_2 = 3.60 \pm 0.03$, $F_1 = 3.10 \pm 0.08 \text{ ppm}$ representing coupling between the H-25 and H-26–$CH_2$–protons of TCBAs (marked as 6a, detected in 9/11 cases). The diagonal peak at $F_2 = F_1 = 0.68 \pm 0.03 \text{ ppm}$ represents TCBAs plus cholesterol (marked as 7, detected in 11/11 cases). It should be noted that the chemical shift values recorded in the 2D spectrum were slightly different from those of the 1D spectrum due to the limited number of data points available in the 2D spectrum in both dimensions.

It should be noted that Fig. 3(B) looks similar to Fig. 3(A) (with some additional noise peaks), showing all the diagonal/cross peaks detected in Fig. 3(A) except for the cross peak 3a. Interestingly, the cross peak marked as 4a ($F_2 = 4.32 \text{ ppm}$, $F_1 = 3.66 \text{ ppm}$), which is very close to the water signal, was also observed. This indicates that the increase in the water suppression band-width (from 35 Hz to 50 Hz) has negligible or no effect on the spectral quality. Similarly, the decrease in the number of increments shows negligible effect in the spectral quality (Fig. 3(C)). This shows that the linear prediction from 40 to 64 increments provided similar results to the linear prediction from 51 to 64 increments.

### DISCUSSION

MRS can reveal subtle changes in biochemistry (due to its high resolution) following the metabolic alterations in the early stages of disease in a single experiment. This makes MRS an attractive tool in medical diagnosis (29,30). In particular, it is a potential
non-invasive tool for differentiating malignant changes from benign disorders (31). In the past, a number of in vitro bile MRS studies introduced the value of this technique in the early diagnosis of HPB disorders (3–8,17,28,32). Bile for such studies was collected during invasive procedures such as endoscopic retrograde cholangiopancreatography (ERCP) or surgery. In vivo MRS would have enormous potential in the non-invasive analysis of bile. The first attempt by Prescott et al. (18) was successful in quantifying only one component of bile, chol-PLs. The spectral quality was low and other components of bile such as GCBAs and TCBAs, which have a major role in the pathophysiology of HPB diseases, were not quantified. This could be due to the low magnetic field strength, the use of spin echoes with long delays, magnetic susceptibilities, motion of the gallbladder, especially due to breathing, and/or lipid contamination. In the second attempt, Künecke et al. obtained a good quality in vivo 1H MR spectrum of gallbladder bile from cynomolgus monkeys using a 4.7 T animal scanner with the aid of a transmit/receive surface coil (19). However, the 4.7 T scanner and transmit/receive surface coils are not routine for clinical use. The current study showed the feasibility of acquiring a good quality 1H MR spectrum under current clinical settings (3T scanner and receive surface array coils).

Figure 3. 2D L-COSY spectrum of human gallbladder bile in vivo obtained from healthy volunteers. (A) Typical in vivo 2D spectrum of bile with water suppression band width of 35 Hz and 50 increments, (B) 2D spectrum with water suppression band width of 50 Hz and 50 increments and (C) 2D spectrum with water suppression band width of 35 Hz and 39 increments. All three spectra are linear predicted to 64 increments. The following diagonal peaks and cross peaks were assigned based on the in vitro studies (8,13): 1, 1a, diagonal and cross peaks representing the amide group of TCBAs and GCBAs; 2, 2a, 2b, diagonal peak representing the olefinic (–CH=CH–) protons of chol-PLs and two cross peaks representing J-coupling of the olefinic protons with neighbouring methylene protons; 3, 3a, diagonal peak representing PC-glyceryl 1-CH2 protons and cross peak representing J-coupling of the glyceryl 2-CH with 3-CH2 of PC; 4, 4a, 4b, diagonal peak representing PC-cholyl- N–CH2– protons and symmetric cross peaks showing J-coupling between –N–CH2– and –CH2–O– of chol-PLs; 5, diagonal peak representing the –N+(CH3)3 group of chol-PLs; 6 and 6a, diagonal peak representing the H-26–CH2– protons of TCBAs and cross peak representing J-coupling between the H-25 and H-26 –CH2– protons of TCBAs; 7, diagonal peak assigned to TBA plus cholesterol.
To overcome some of the limitations of the previous study in humans (18), we employed a field strength of 3 T, and decreased $T_2$ from 60 to 30 ms, which can significantly reduce the $T_2$ loss. Moreover, we used a bellow respiratory-gated sequence to reduce the motion artifacts due to breathing. With these improvements, we were able to quantify other major lipid components of bile – TBAs plus cholesterol, TCBAs and GCBAs, including the previously reported chol-PLs (18). The peak resonating at 0.66 ppm has contributions from the H-18 methyl protons of TBAs and cholesterol. However, earlier in vivo studies have revealed that the percentage of cholesterol contributing to this signal is very low. As a result, the peak mostly represents the sum of TCBAs and GCBAs (10). This fact could partially be explained by the lower mobility of cholesterol molecules due to their participation in phospholipid membranes. This results in loss of cholesterol signals due to shorter $T_2$ relaxation time (33). However, in the current study, the concentration of TBAs + cholesterol quantified from the 0.66 ppm peak was 123.47 ± 59.09 mM (mean ± SD), which is higher than in the previous in vitro studies (TBAs + cholesterol 72.76 ± 55.06 mM, mean ± SD, as reported by Gowda et al. (29)). However, most of the individual values (except in three cases, Table 4) fall in the range 0.38–178.61 mM, as reported by Gowda et al. (29). In the majority of in vitro studies, the samples were collected from participants who were suffering from some sort of HPB disorder, the major reason for ERCP to be performed. As a result, the concentrations determined in in vitro studies may reasonably be expected to differ from our in vivo results gathered non-invasively from healthy volunteers, without any medical interference and use of radiopaque agents.

Given that the TBA pool in the bile is almost completely conjugated to glycine and/or taurine, and under the conditions of low biliary cholesterol, the levels of lipids determined from the 0.66 ppm peak should be comparable to the sum of TCBAs and GCBAs (10). However, in the current study, the mean concentration of lipids calculated from the 0.66 ppm peak was 53% higher than the mean of the sum of GCBAs and TCBAs (as opposed to the 10% expected) due to contamination from cholesterol (19,34). Surprisingly, the study by Künnecke et al. (19) on the gallbladder bile of monkeys revealed even higher concentrations of lipids in this region (267 ± 47 mM; mean ± SD). One explanation could be the effect of lipid contamination by body fat surrounding the gallbladder in in vivo studies. Although we used spatial saturation bands around the gallbladder to suppress the contribution from outside fat, it is difficult to remove such effects completely. Despite the use of respiratory-gated sequences, a residual breathing motion artifact may also contribute to the apparent lipid contamination.

Since a majority of bile acids in bile are conjugated to glycine and/or taurine, Ijare et al. explored the use of the amide protons of conjugated bile acids (resonating in the region 7.80–8.10 ppm) to quantify the sum of GCBAs and TCBAs for in vitro applications (13). However, the amide protons are in dynamic exchange with biliary water at physiologic pH (7.0–7.7) (35), and do not represent the true signal intensity. As a result, one of the prerequisites for using such a methodology was to adjust the pH of bile to a value slightly lower than the physiologic pH (6 ± 0.5). In in vivo studies such manipulation of pH is not possible; however, the pH of bile is generally decreased during its concentration in the gallbladder (36). This could be an advantage for in vivo studies. We mostly recruited subjects who had fasted overnight or for at least four hours in order to have a gallbladder that was completely filled with bile. Therefore, the pH of bile should not affect the signal intensity of amide protons in the bile concentrated after overnight fasting. Based on Table 4, in most cases the concentrations of GCBAs and TCBAs calculated from the amide region are slightly less than the sums of concentrations calculated from 3.74 and 3.08 peaks. In two cases the signal from the amide region was not detected. This could be due to the very high pH of the bile. However, in three cases the concentrations of GCBAs and TCBAs calculated from the amide region were slightly more than the sums of concentrations of GCBAs and TCBAs calculated from 3.74 and 3.08 peaks. Considering the breadth of the amide region, there could be a random error in measuring the area under these peaks.

A more accurate method of quantifying TCBAs and GCBAs is to use their –CH$_2$– peaks resonating at 3.08 and 3.74 ppm, respectively (10). This approach is independent of the pH effect. Moreover, these peaks are not affected by lipid contamination. Since the ratio of GCBAs/TCBAs plays an important role in HPB disorders (10), determining this ratio may be valuable in the diagnosis of HPB diseases. In this study, the mean of the GCBAs/TCBA ratio was 2.48 (2.48 ± 1.51, mean ± SD), which is very close to the expected value, 3 (37). However, there were cases in which this ratio was even less than unity. Given the small sample size, it is difficult to draw a rigorous conclusion in this study. The chol-PLs were quantified from the signal resonating at 3.22 ppm following a strategy similar to that of Prescot et al. (18). The levels of chol-PLs determined in this study (47.58 ± 20.65 mM, mean ± SD) were comparable to those reported earlier (35.8 ± 9.8 mM, mean ± SD) (18).

As presented in Table 4, there was a considerable variability in the concentration of biliary metabolites, which may raise concerns regarding the diagnostic value of these metabolites. Such variability was reported in previous in vitro (29) and in vivo (18) studies as well. As explained by Khan et al. (17), the concentration of bile metabolites varies between subjects and within a subject over time. This is primarily due to variations in diet, nutritional status, drugs and environmental exposure. In an in vitro study by Albii et al. (7), although there were similar variabilities, the differences between normalized intensities of PC and TCBAs in non-cancer and cancer patients were statistically significant. In this study, although there is a considerable variability in the concentrations of bile metabolites, the quantification of these metabolites is still useful and can be used for the differentiation of various HPB disorders.

Considering that age, sex, variation in diet, and exposure to xenobiotics are partly responsible for the variation in the concentrations of biliary metabolites (17,19), eliminating such confounding factors may help decrease the variability. In the study by Künnecke et al. (19), the researchers selected male monkeys with similar ages and put them on a similar diet. This reduced the SD in the TBA measurements to less than 20% of the mean. Based on this study, one can infer that the biliary metabolites represent the individual’s metabolism, and if we follow the bile composition in the same patient over time we may be able to follow up the progress of the disease, which can be quite useful in the clinic.

1D spectra cannot provide complete information regarding the metabolite composition of the bile. Furthermore, signals arising from some of the bile metabolites important in HPB pathologies, such as lactate and the glycercyl region of PC, overlap with lipid signals (8). Moreover, some important regions such as the amide region have a very low intensity in the 1D spectrum.
and are not detectable in some subjects. In order to detect such signals separately, 2D L-COSY spectra (15,16) were obtained for the first time from human gallbladder bile in vivo. A cross peak from the PC-glycerol signals ($F_2 = 5.28 \pm 0.04$, $F_1 = 4.25 \pm 0.07$ ppm) has been detected in the L-COSY spectrum, which overlapped the lipid signal in the corresponding 1D spectrum. Detection of these signals may be helpful in the diagnosis of HPB pathologies (8).

This was the first attempt to obtain 2D spectra from the gallbladder in vivo, which is a moving organ. Although we were able to detect and assign some cross peaks with clinical importance based on their chemical shifts observed in vitro, the quantification was not reliable due to high levels of noise. The quality of the 2D spectra should be improved further by increasing signal-to-noise ratio (using higher magnetic field strength and better RF coils), decreasing echo time and decreasing $F_1$ noise in order to achieve a reliable volume measurement of cross peaks. Therefore, in this study, we are presenting the first 2D L-COSY spectra from bile inside the gallbladder only qualitatively.

CONCLUSIONS

This study showed the possibility of obtaining good quality 1D $^1$H MR spectra of gallbladder bile in vivo using a 3 T clinical scanner. It facilitated the simultaneous quantification of TBAs plus cholesterol, TCBAs, and GCBAs, including the previously reported chol-PLs, which have a major role in the pathophysiology of HPB diseases. This approach may be helpful in the early non-invasive diagnosis of HPB disorders. Detection of PC-glycerol signals in the L-COSY spectrum, which overlapped with the lipid signal in the corresponding 1D spectrum, can prove the value of 2D techniques in the differentiation of PC from its hydrolysis products such as lysophosphatidylcholine and phosphorylcholine, which are detrimental to the HPB system. Moreover, 2D techniques can augment the diagnostic accuracy of 1D methods. However, 2D techniques are time consuming and warrant further development in order to improve the spectral quality and reduce scanning time.

REFERENCES